Phase II study of three days' fractionated dosage of ifosfamide, epirubicin and cisplatin in small cell lung cancer.
Thongprasert
S
S
Division of Medical Oncology, Faculty of Medicine, Chiang Mai University, Thailand.
Phromwas
N
N
Atikachi
B
B
Jiemsripong
K
K
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male
D015251:Epirubicin; D002945:Cisplatin; D007069:Ifosfamide